Seminars in Diagnostic Pathology
Volume 26, Issue 2 , Pages 89-102 , May 2009

Vasculitis affecting the kidney

  • Rohan John
    • ,
  • Andrew M. Herzenberg

      Affiliations

    • Corresponding Author InformationAddress reprint requests and correspondence: Andrew M. Herzenberg, Department of Pathology, University Health Network, 11 Eaton, 200 Elizabeth St, Toronto, ON, M5G 2C4, Canada

References 

  1. Rao JK, Allen NB, Pincus T. Limitations of the 1990 American College of Rheumatology classification criteria in the diagnosis of vasculitis. Ann Intern Med. 1998;129:345–352
  2. Zeek PM. Periarteritis nodosa; a critical review. Am J Clin Pathol. 1952;22:777–790
  3. Cohen BA, Clark WF. Pauci-immune renal vasculitis: Natural history, prognostic factors, and impact of therapy. Am J Kidney Dis. 2000;36:914–924
  4. Lie JT. Nomenclature and classification of vasculitis: Plus ca change, plus c'est la meme chose. Arthritis Rheum. 1994;37:181–186
  5. Hunder GG, Arend WP, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of vasculitis (Introduction). Arthritis Rheum. 1990;33:1065–1067
  6. Jennette JC, Falk RJ, Andrassy K, et al. Nomenclature of systemic vasculitides (Proposal of an international consensus conference). Arthritis Rheum. 1994;37:187–192
  7. Davies DJ. Small vessel vasculitis. Cardiovasc Pathol. 2005;14:335–346
  8. Booth AD, Almond MK, Burns A, et al. Outcome of ANCA-associated renal vasculitis: A 5-year retrospective study. Am J Kidney Dis. 2003;41:776–784
  9. Stilmant MM, Bolton WK, Sturgill BC, et al. Crescentic glomerulonephritis without immune deposits: Clinicopathologic features. Kidney Int. 1979;15:184–195
  10. Kallenberg CG. Antineutrophil cytoplasmic antibodies (ANCA) and vasculitis. Clin Rheumatol. 1990;9:132–135
  11. Jennette JC, Wilkman AS, Falk RJ. Anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and vasculitis. Am J Pathol. 1989;135:921–930
  12. Falk RJ, Jennette JC. ANCA small-vessel vasculitis. J Am Soc Nephrol. 1997;8:314–322
  13. Morgan MD, Harper L, Williams J, et al. Anti-neutrophil cytoplasm-associated glomerulonephritis. J Am Soc Nephrol. 2006;17:1224–1234
  14. Fauci AS, Haynes B, Katz P. The spectrum of vasculitis: Clinical, pathologic, immunologic and therapeutic considerations. Ann Intern Med. 1978;89:660–676
  15. Carlson JA, Ng BT, Chen KR. Cutaneous vasculitis update: Diagnostic criteria, classification, epidedmiology, etiology, pathogenesis, evaluation and prognosis. Am J Dermatopathol. 2005;27:504–528
  16. Jennette JC, Falk RJ. Small-vessel vasculitis. N Engl J Med. 1997;337:1512–1523
  17. Fauci AS, Wolff SM. Wegener's granulomatosis: Studies in eighteen patients and a review of the literature. Medicine (Baltimore). 1973;52:535–561
  18. Davies DJ, Moran JE, Niall JF, et al. Segmental necrotising glomerulonephritis with antineutrophil antibody: Possible arbovirus aetiology?. Br Med J (Clin Res Ed). 1982;285:606
  19. van der Woude FJ, Rasmussen N, Lobatto S, et al. Autoantibodies against neutrophils and monocytes: Tool for diagnosis and marker of disease activity in Wegener's granulomatosis. Lancet. 1985;1:425–429
  20. Falk RJ, Jennette JC. Anti-neutrophil cytoplasmic autoantibodies with specificity for myeloperoxidase in patients with systemic vasculitis and idiopathic necrotizing and crescentic glomerulonephritis. N Engl J Med. 1988;318:1651–1657
  21. Jenne DE, Tschopp J, Ludemann J, et al. Wegener's autoantigen decoded. Nature. 1990;346:520
  22. Savige JA, Paspaliaris B, Silvestrini R, et al. A review of immunofluorescent patterns associated with antineutrophil cytoplasmic antibodies (ANCA) and their differentiation from other antibodies. J Clin Pathol. 1998;51:568–575
  23. Hagen EC, Daha MR, Hermans J, et al. Diagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies in idiopathic systemic vasculitis (EC/BCR Project for ANCA Assay Standardization). Kidney Int. 1998;53:743–753
  24. Savige J, Davies D, Falk RJ, et al. Antineutrophil cytoplasmic antibodies and associated diseases: A review of the clinical and laboratory features. Kidney Int. 2000;57:846–862
  25. Vizjak A, Nagode B, Rott T, et al. Antineutrophil cytoplasmic autoantibodies-antigen specificity and associated diseases. Wien Klin Wochenschr. 2000;112:665–670
  26. Savige J, Gillis D, Benson E, et al. International Consensus Statement on Testing and Reporting of Antineutrophil Cytoplasmic Antibodies (ANCA). Am J Clin Pathol. 1999;111:507–513
  27. Jennette JC, Falk RJ. New insight into the pathogenesis of vasculitis associated with antineutrophil cytoplasmic autoantibodies. Curr Opin Rheumatol. 2008;20:55–60
  28. Falk RJ, Jennette JC. ANCA are pathogenic—Oh yes they are!. J Am Soc Nephrol. 2002;13:1977–1979
  29. Kallenberg CG. Pathogenesis of PR3-ANCA associated vasculitis. J Autoimmun. 2008;30:29–36
  30. Kallenberg CG, Heeringa P, Stegeman CA. Mechanisms of disease: Pathogenesis and treatment of ANCA-associated vasculitides. Nat Clin Pract Rheumatol. 2006;2:661–670
  31. Falk RJ, Terrell RS, Charles LA, et al. Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro. Proc Natl Acad Sci U S A. 1990;87:4115–4119
  32. Savage CO, Pottinger BE, Gaskin G, et al. Autoantibodies developing to myeloperoxidase and proteinase 3 in systemic vasculitis stimulate neutrophil cytotoxicity toward cultured endothelial cells. Am J Pathol. 1992;141:335–342
  33. Rarok AA, Limburg PC, Kallenberg CG. Neutrophil-activating potential of antineutrophil cytoplasm autoantibodies. J Leukoc Biol. 2003;74:3–15
  34. Falk RJ, Hogan S, Carey TS, et al. Clinical course of anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and systemic vasculitis (The Glomerular Disease Collaborative Network). Ann Intern Med. 1990;113:656–663
  35. Ralston DR, Marsh CB, Lowe MP, et al. Antineutrophil cytoplasmic antibodies induce monocyte IL-8 release (Role of surface proteinase-3, alpha1-antitrypsin, and Fcgamma receptors). J Clin Invest. 1997;100:1416–1424
  36. Weidner S, Neupert W, Goppelt-Struebe M, et al. Antineutrophil cytoplasmic antibodies induce human monocytes to produce oxygen radicals in vitro. Arthritis Rheum. 2001;44:1698–1706
  37. Sanders JS, Huitma MG, Kallenberg CG, et al. Prediction of relapses in PR3-ANCA-associated vasculitis by assessing responses of ANCA titres to treatment. Rheumatology (Oxford). 2006;45:724–729
  38. Boomsma MM, Stegeman CA, van der Leij MJ, et al. Prediction of relapses in Wegener's granulomatosis by measurement of antineutrophil cytoplasmic antibody levels: A prospective study. Arthritis Rheum. 2000;43:2025–2033
  39. Schlieben DJ, Korbet SM, Kimura RE, et al. Pulmonary-renal syndrome in a newborn with placental transmission of ANCAs. Am J Kidney Dis. 2005;45:758–761
  40. Harper JM, Thiru S, Lockwood CM, et al. Myeloperoxidase autoantibodies distinguish vasculitis mediated by anti-neutrophil cytoplasm antibodies from immune complex disease in MRL/Mp-lpr/lpr mice: A spontaneous model for human microscopic angiitis. Eur J Immunol. 1998;28:2217–2226
  41. Heeringa P, Brouwer E, Klok PA, et al. Autoantibodies to myeloperoxidase aggravate mild anti-glomerular-basement-membrane-mediated glomerular injury in the rat. Am J Pathol. 1996;149:1695–1706
  42. Brouwer E, Huitema MG, Klok PA, et al. Antimyeloperoxidase-associated proliferative glomerulonephritis: An animal model. J Exp Med. 1993;177:905–914
  43. Little MA, Smyth CL, Yadav R, et al. Antineutrophil cytoplasm antibodies directed against myeloperoxidase augment leukocyte-microvascular interactions in vivo. Blood. 2005;106:2050–2058
  44. Xiao H, Heeringa P, Hu P, et al. Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest. 2002;110:955–963
  45. Xiao H, Heeringa P, Liu Z, et al. The role of neutrophils in the induction of glomerulonephritis by anti-myeloperoxidase antibodies. Am J Pathol. 2005;167:39–45
  46. Huugen D, Xiao H, van Esch A, et al. Aggravation of anti-myeloperoxidase antibody-induced glomerulonephritis by bacterial lipopolysaccharide: Role of tumor necrosis factor-alpha. Am J Pathol. 2005;167:47–58
  47. Xiao H, Schreiber A, Heeringa P, et al. Alternative complement pathway in the pathogenesis of disease mediated by anti-neutrophil cytoplasmic autoantibodies. Am J Pathol. 2007;170:52–64
  48. Huugen D, van Esch A, Xiao H, et al. Inhibition of complement factor C5 protects against anti-myeloperoxidase antibody-mediated glomerulonephritis in mice. Kidney Int. 2007;71:646–654
  49. Cunningham MA, Huang XR, Dowling JP, et al. Prominence of cell-mediated immunity effectors in “pauci-immune” glomerulonephritis. J Am Soc Nephrol. 1999;10:499–506
  50. Weidner S, Carl M, Riess R, et al. Histologic analysis of renal leukocyte infiltration in antineutrophil cytoplasmic antibody-associated vasculitis: Importance of monocyte and neutrophil infiltration in tissue damage. Arthritis Rheum. 2004;50:3651–3657
  51. de Lind van Wijngaarden RA, van Rijn L, Hagen EC, et al. Hypotheses on the etiology of antineutrophil cytoplasmic autoantibody associated vasculitis: The cause is hidden, but the result is known. Clin J Am Soc Nephrol. 2008;3:237–252
  52. Nowack R, Lehmann H, Flores-Suarez LF, et al. Familial occurrence of systemic vasculitis and rapidly progressive glomerulonephritis. Am J Kidney Dis. 1999;34:364–373
  53. Morita S, Ueda Y, Eguchi K. Anti-thyroid drug-induced ANCA-associated vasculitis: A case report and review of the literature. Endocr J. 2000;47:467–470
  54. Gao Y, Zhao MH, Guo XH, et al. The prevalence and target antigens of antithyroid drugs induced antineutrophil cytoplasmic antibodies (ANCA) in Chinese patients with hyperthyroidism. Endocr Res. 2004;30:205–213
  55. Schreiber A, Luft FC, Kettritz R. Membrane proteinase 3 expression and ANCA-induced neutrophil activation. Kidney Int. 2004;65:2172–2183
  56. Stegeman CA, Tervaert JW, Sluiter WJ, et al. Association of chronic nasal carriage of Staphylococcus aureus and higher relapse rates in Wegener's granulomatosis. Ann Intern Med. 1994;120:12–17
  57. Pendergraft WF, Preston GA, Shah RR, et al. Autoimmunity is triggered by cPR-3(105-201), a protein complementary to human autoantigen proteinase-3. Nat Med. 2004;10:72–79
  58. Bautz DJ, Preston GA, Lionaki S, et al. Antibodies with dual reactivity to plasminogen and complementary PR3 in PR3-ANCA vasculitis. J Am Soc Nephrol. 2008;19:2421–2429
  59. Jennette JC, Thomas DB. Crescentic glomerulonephritis. Nephrol Dial Transplant. 2001;16(suppl 6):80–82
  60. Saxena R, Bygren P, Arvastson B, et al. Circulating autoantibodies as serological markers in the differential diagnosis of pulmonary renal syndrome. J Intern Med. 1995;238:143–152
  61. Niles JL, Bottinger EP, Saurina GR, et al. The syndrome of lung hemorrhage and nephritis is usually an ANCA-associated condition. Arch Intern Med. 1996;156:440–445
  62. Hauer HA, Bajema IM, de Heer E, et al. Distribution of renal lesions in idiopathic systemic vasculitis: A three-dimensional analysis of 87 glomeruli. Am J Kidney Dis. 2000;36:257–265
  63. Magil AB. Histogenesis of glomerular crescents (Immunohistochemical demonstration of cytokeratin in crescent cells). Am J Pathol. 1985;120:222–229
  64. Boucher A, Droz D, Adafer E, et al. Relationship between the integrity of Bowman's capsule and the composition of cellular crescents in human crescentic glomerulonephritis. Lab Invest. 1987;56:526–533
  65. Hauer HA, Bajema IM, van Houwelingen HC, et al. Renal histology in ANCA-associated vasculitis: Differences between diagnostic and serologic subgroups. Kidney Int. 2002;61:80–89
  66. Jennette JC. Rapidly progressive crescentic glomerulonephritis. Kidney Int. 2003;63:1164–1177
  67. Savage CO, Winearls CG, Evans DJ, et al. Microscopic polyarteritis: Presentation, pathology and prognosis. Q J Med. 1985;56:467–483
  68. Vizjak A, Rott T, Koselj-Kajtna M, et al. Histologic and immunohistologic study and clinical presentation of ANCA-associated glomerulonephritis with correlation to ANCA antigen specificity. Am J Kidney Dis. 2003;41:539–549
  69. Bonsib SM, Goeken JA. Renal artery stenosis modifies glomerular injury in antineutrophil cytoplasmic antibody-associated disease. Am J Kidney Dis. 1992;20:509–512
  70. Bonsib SM, Goeken JA, Fandel T, et al. Necrotizing medullary lesions in patients with ANCA associated renal disease. Mod Pathol. 1994;7:181–185
  71. Bajema IM, Hagen EC, Ferrario F, et al. Renal granulomas in systemic vasculitis (EC/BCR Project for ANCA-Assay Standardization). Clin Nephrol. 1997;48:16–21
  72. Bajema IM, Hagen EC, van der Woude FJ, et al. Wegener's granulomatosis: A meta-analysis of 349 literary case reports. J Lab Clin Med. 1997;129:17–22
  73. Haas M, Eustace JA. Immune complex deposits in ANCA-associated crescentic glomerulonephritis: A study of 126 cases. Kidney Int. 2004;65:2145–2152
  74. Rutgers A, Slot M, van Paassen P, et al. Coexistence of anti-glomerular basement membrane antibodies and myeloperoxidase-ANCAs in crescentic glomerulonephritis. Am J Kidney Dis. 2005;46:253–262
  75. Tse WY, Howie AJ, Adu D, et al. Association of vasculitic glomerulonephritis with membranous nephropathy: A report of 10 cases. Nephrol Dial Transplant. 1997;12:1017–1027
  76. Haas M, Jafri J, Bartosh SM, et al. ANCA-associated crescentic glomerulonephritis with mesangial IgA deposits. Am J Kidney Dis. 2000;36:709–718
  77. Hellmark T, Niles JL, Collins AB, et al. Comparison of anti-GBM antibodies in sera with or without ANCA. J Am Soc Nephrol. 1997;8:376–385
  78. Sinico RA, Di Toma L, Maggiore U, et al. Renal involvement in Churg-Strauss syndrome. Am J Kidney Dis. 2006;47:770–779
  79. Guillevin L, Lhote F. Distinguishing polyarteritis nodosa from microscopic polyangiitis and implications for treatment. Curr Opin Rheumatol. 1995;7:20–24
  80. Woywodt A, Haubitz M, Haller H, et al. Wegener's granulomatosis. Lancet. 2006;367:1362–1366
  81. Woywodt A, Matteson EL. Wegener's granulomatosis—Probing the untold past of the man behind the eponym. Rheumatology (Oxford). 2006;45:1303–1306
  82. Sable-Fourtassou R, Cohen P, Mahr A, et al. Antineutrophil cytoplasmic antibodies and the Churg-Strauss syndrome. Ann Intern Med. 2005;143:632–638
  83. Sinico RA, Di Toma L, Maggiore U, et al. Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg-Strauss syndrome. Arthritis Rheum. 2005;52:2926–2935
  84. Kallenberg CG. Churg-Strauss syndrome: Just one disease entity?. Arthritis Rheum. 2005;52:2589–2593
  85. Trejo O, Ramos-Casals M, Garcia-Carrasco M, et al. Cryoglobulinemia: Study of etiologic factors and clinical and immunologic features in 443 patients from a single center. Medicine (Baltimore). 2001;80:252–262
  86. Roccatello D, Fornasieri A, Giachino O, et al. Multicenter study on hepatitis C virus-related cryoglobulinemic glomerulonephritis. Am J Kidney Dis. 2007;49:69–82
  87. Karras A, Noel LH, Droz D, et al. Renal involvement in monoclonal (type i) cryoglobulinemia: Two cases associated with IgG3 kappa cryoglobulin. Am J Kidney Dis. 2002;40:1091–1096
  88. Tarantino A, Campise M, Banfi G, et al. Long-term predictors of survival in essential mixed cryoglobulinemic glomerulonephritis. Kidney Int. 1995;47:618–623
  89. D'Amico G. Renal involvement in hepatitis C infection: Cryoglobulinemic glomerulonephritis. Kidney Int. 1998;54:650–671
  90. Ferrario F, Castiglione A, Colasanti G, et al. The detection of monocytes in human glomerulonephritis. Kidney Int. 1985;28:513–519
  91. Beddhu S, Bastacky S, Johnson JP. The clinical and morphologic spectrum of renal cryoglobulinemia. Medicine (Baltimore). 2002;81:398–409
  92. Ogihara T, Saruta T, Saito I, et al. Finger print deposits of the kidney in pure monoclonal IgG kappa cryoglobulinemia. Clin Nephrol. 1979;12:186–190
  93. Davin JC, Ten Berge IJ, Weening JJ. What is the difference between IgA nephropathy and Henoch-Schonlein purpura nephritis?. Kidney Int. 2001;59:823–834
  94. Shrestha S, Sumingan N, Tan J, et al. Henoch Schonlein purpura with nephritis in adults: Adverse prognostic indicators in a UK population. QJM. 2006;99:253–265
  95. Magro CM, Crowson AN. A clinical and histologic study of 37 cases of immunoglobulin A-associated vasculitis. Am J Dermatopathol. 1999;21:234–240
  96. Pillebout E, Thervet E, Hill G, et al. Henoch-Schonlein purpura in adults: Outcome and prognostic factors. J Am Soc Nephrol. 2002;13:1271–1278
  97. Descombes E, Droz D, Drouet L, et al. Renal vascular lesions in lupus nephritis. Medicine (Baltimore). 1997;76:355–368
  98. Weening JJ, D'Agati VD, Schwartz MM, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol. 2004;15:241–250
  99. Appel GB, Pirani CL, D'Agati V. Renal vascular complications of systemic lupus erythematosus. J Am Soc Nephrol. 1994;4:1499–1515
  100. Banfi G, Bertani T, Boeri V, et al. Renal vascular lesions as a marker of poor prognosis in patients with lupus nephritis (Gruppo Italiano per lo Studio della Nefrite Lupica (GISNEL)). Am J Kidney Dis. 1991;18:240–248
  101. Grishman E, Venkataseshan VS. Vascular lesions in lupus nephritis. Mod Pathol. 1988;1:235–241
  102. Appel GB, Silva FG, Pirani CL, et al. Renal involvement in systemic lupus erythematosus (SLE): A study of 56 patients emphasizing histologic classification. Medicine (Baltimore). 1978;57:371–410
  103. Nasr SH, D'Agati VD, Park HR, et al. Necrotizing and crescentic lupus nephritis with antineutrophil cytoplasmic antibody seropositivity. Clin J Am Soc Nephrol. 2008;3:682–690
  104. Lewis EJ, Schwartz MM, Korbet SM. Severe lupus nephritis: Importance of re-evaluating the histologic classification and the approach to patient care. J Nephrol. 2001;14:223–227
  105. Markowitz GS, D'Agati VD. The ISN/RPS 2003 classification of lupus nephritis: An assessment at 3 years. Kidney Int. 2007;71:491–495
  106. Helin HJ, Korpela MM, Mustonen JT, et al. Renal biopsy findings and clinicopathologic correlations in rheumatoid arthritis. Arthritis Rheum. 1995;38:242–247
  107. Boers M, Croonen AM, Dijkmans BA, et al. Renal findings in rheumatoid arthritis: Clinical aspects of 132 necropsies. Ann Rheum Dis. 1987;46:658–663
  108. Harper L, Cockwell P, Howie AJ, et al. Focal segmental necrotizing glomerulonephritis in rheumatoid arthritis. QJM. 1997;90:125–132
  109. Qarni MU, Kohan DE. Pauci-immune necrotizing glomerulonephritis complicating rheumatoid arthritis. Clin Nephrol. 2000;54:54–58
  110. Stokes MB, Foster K, Markowitz GS, et al. Development of glomerulonephritis during anti-TNF-alpha therapy for rheumatoid arthritis. Nephrol Dial Transplant. 2005;20:1400–1406
  111. Mustila A, Korpela M, Mustonen J, et al. Perinuclear antineutrophil cytoplasmic antibody in rheumatoid arthritis: A marker of severe disease with associated nephropathy. Arthritis Rheum. 1997;40:710–717
  112. Moreland L, DiBartolomeo A, Brick J. Rheumatoid vasculitis with intrarenal aneurysm formation. J Rheumatol. 1988;15:845–849
  113. Skopouli FN. Kidney injury in Sjogren's syndrome. Nephrol Dial Transplant. 2001;16(suppl 6):63–64
  114. Goules A, Masouridi S, Tzioufas AG, et al. Clinically significant and biopsy-documented renal involvement in primary Sjogren syndrome. Medicine (Baltimore). 2000;79:241–249
  115. Molina R, Provost TT, Alexander EL. Two types of inflammatory vascular disease in Sjogren's syndrome (Differential association with seroreactivity to rheumatoid factor and antibodies to Ro (SS-A) and with hypocomplementemia). Arthritis Rheum. 1985;28:1251–1258
  116. Henegar C, Pagnoux C, Puechal X, et al. A paradigm of diagnostic criteria for polyarteritis nodosa: Analysis of a series of 949 patients with vasculitides. Arthritis Rheum. 2008;58:1528–1538
  117. Agard C, Mouthon L, Mahr A, et al. Microscopic polyangiitis and polyarteritis nodosa: How and when do they start?. Arthritis Rheum. 2003;49:709–715
  118. Guillevin L, Mahr A, Callard P, et al. Hepatitis B virus-associated polyarteritis nodosa: Clinical characteristics, outcome, and impact of treatment in 115 patients. Medicine (Baltimore). 2005;84:313–322
  119. Lhote F, Cohen P, Guillevin L. Polyarteritis nodosa, microscopic polyangiitis and Churg-Strauss syndrome. Lupus. 1998;7:238–258
  120. Trepo C, Guillevin L. Polyarteritis nodosa and extrahepatic manifestations of HBV infection: The case against autoimmune intervention in pathogenesis. J Autoimmun. 2001;16:269–274
  121. Newburger JW, Fulton DR. Kawasaki disease. Curr Opin Pediatr. 2004;16:508–514
  122. Wang JN, Chiou YY, Chiu NT, et al. Renal scarring sequelae in childhood Kawasaki disease. Pediatr Nephrol. 2007;22:684–689
  123. Falcini F, Calabri GB, Simonini G, et al. Bilateral renal artery stenosis in Kawasaki disease: A report of two cases. Clin Exp Rheumatol. 2006;24:719–721
  124. Burns JC, Glode MP. Kawasaki syndrome. Lancet. 2004;364:533–544
  125. Hall JK. Giant-cell arteritis. Curr Opin Ophthalmol. 2008;19:454–460
  126. Chatelain D, Duhaut P, Loire R, et al. Small-vessel vasculitis surrounding an uninflamed temporal artery: A new diagnostic criterion for polymyalgia rheumatica?. Arthritis Rheum. 2008;58:2565–2573
  127. Weyand CM, Ma-Krupa W, Goronzy JJ. Immunopathways in giant cell arteritis and polymyalgia rheumatica. Autoimmun Rev. 2004;3:46–53
  128. Lambert M, Weber A, Boland B, et al. Large vessel vasculitis without temporal artery involvement: Isolated form of giant cell arteritis?. Clin Rheumatol. 1996;15:174–180
  129. Small P, Brisson ML. Wegener's granulomatosis presenting as temporal arteritis. Arthritis Rheum. 1991;34:220–223
  130. Bert RJ, Antonacci VP, Berman L, et al. Polyarteritis nodosa presenting as temporal arteritis in a 9-year-old child. AJNR Am J Neuroradiol. 1999;20:167–171
  131. Vanderschueren S, Depoot I, Knockaert DC, et al. Microscopic haematuria in giant cell arteritis. Clin Rheumatol. 2002;21:373–377
  132. Medvedev G, Al-Shamari AE, Copland MA, et al. Isolated renal giant cell arteritis. Am J Kidney Dis. 2002;40:658–661
  133. Lupi-Herrera E, Sanchez-Torres G, Marcushamer J, et al. Takayasu's arteritis (Clinical study of 107 cases). Am Heart J. 1977;93:94–103
  134. Hall S, Barr W, Lie JT, et al. Takayasu's arteritis (A study of 32 North American patients). Medicine (Baltimore). 1985;64:89–99
  135. Chugh KS, Jain S, Sakhuja V, et al. Renovascular hypertension due to Takayasu's arteritis among Indian patients. Q J Med. 1992;85:833–843
  136. Yoshimura M, Kida H, Saito Y, et al. Peculiar glomerular lesions in Takayasu's arteritis. Clin Nephrol. 1985;24:120–127

PII: S0740-2570(09)00017-3

doi: 10.1053/j.semdp.2009.08.001

Seminars in Diagnostic Pathology
Volume 26, Issue 2 , Pages 89-102 , May 2009

Article Tools

* Image Usage & Resolution